Askarian Mehrdad, Dianat Sara, Tahmasebi Sedigheh, Jafari Abdosaleh, Hatam Nahid
Department of Community Medicine, School of Medicine, Nephro-Urology Research Center Internal Medicine Research Institute, Shiraz University of Medical Sciences, Shiraz, Iran, Shiraz.
Department of Health Management, Student Research Committee, MSc in Health Care Management, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Int J Prev Med. 2022 Nov 28;13:147. doi: 10.4103/ijpvm.IJPVM_611_20. eCollection 2022.
Breast cancer is the most common cancer in the world, which accounts for 21.4% of all kinds of cancers for women in Iran. However, the treatment of breast cancer is costly and given that the budget devoted to the healthcare sector is limited, the present study aimed to investigate the cost-effectiveness of breast cancer screening for women, who referred to breast clinic located in Shahid Motahari clinic affiliated to Shiraz University of Medical Sciences, Shiraz city, Iran in 2017-2018.
This study is a cross-sectional study analyzing the cost-effectiveness of breast cancer screening versus no screening. The study was conducted on 3500 women, who referred to the breast clinic in Motahari clinic, at 2017-2018 in Shiraz, Iran. The patients were identified and direct costs, which were correlated to cancer breast screening, were calculated based on the patients' records with public tariff per person. Tree age pro 2011 used to analyze cost effectiveness.
Based on the results obtained, the expected cost of screening and no screening were 7556 $ppp and 7840 $ppp, respectively. Given their difference in effectiveness (16%), screening was dominant (less costly and more effective) compared to no screening. Tornado diagram showed that the results had the maximum sensitivity to the increase in screening cost.
In general, according to the results obtained from the current study, the screening was more cost effective compared with no screening.
乳腺癌是全球最常见的癌症，在伊朗占女性各类癌症的21.4%。然而，乳腺癌治疗费用高昂，鉴于医疗保健部门的预算有限，本研究旨在调查2017 - 2018年转诊至伊朗设拉子市设拉子医科大学附属沙希德·莫塔哈里诊所乳腺科的女性进行乳腺癌筛查的成本效益。
本研究是一项横断面研究，分析乳腺癌筛查与不筛查的成本效益。该研究对2017 - 2018年转诊至设拉子莫塔哈里诊所乳腺科的3500名女性进行。识别患者，并根据患者记录和每人的公共收费标准计算与乳腺癌筛查相关的直接成本。使用Tree age pro 2011分析成本效益。
根据所得结果，筛查和不筛查的预期成本分别为每人7556国际元（购买力平价）和7840国际元（购买力平价）。鉴于其有效性差异（16%），与不筛查相比，筛查具有优势（成本更低且更有效）。龙卷风图显示结果对筛查成本增加的敏感性最高。
总体而言，根据本研究所得结果，与不筛查相比，筛查更具成本效益。
